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ABSTRACT 
HIV-infected patients on antiretroviral therapy (ART) may present low-level viremia (LLV) above the 
detection level of current viral load assays. In many cases LLV is persistent but does not result in 
overt treatment failure or selection of drug resistant viral variants. To elucidate whether LLV reflects 
active virus replication, we extensively sequenced pol and env genes of the viral populations present 
before and during LLV in 18 patients and searched for indications of genetic evolution. Maximum 
likelihood phylogenetic trees were inspected for temporal structure both visually and by linear 
regression analysis of root-to-tip and pairwise distances. Viral coreceptor tropism was assessed at 
different time points before and during LLV. In none of the patients consistent indications for genetic 
evolution were found over a median period of 4.8 years of LLV. As such these findings could not 
provide evidence that active virus replication is the main driver of LLV. 
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INTRODUCTION 
Patients on combined antiretroviral therapy (ART) may continue to express small traces of virus in 
their plasma, in some cases exceeding the detection level of commercially available viral load (VL) 
assays. This so called low-level viremia (LLV) may persist for longer periods of time. From our 
previous work we learned that persistent LLV, in most cases, does not result in treatment failure or 
selection of drug resistance [1]. The absence of drug resistance mutations (DRM) is clinically 
reassuring, but it cannot exclude a role of active viral replication in LLV. A recent study by Lorenzo-
Redondo et al. (2016) again emphasized the potential role of anatomic sites in the tissues (e.g. lymph 
nodes) that are insufficiently reached by ART and may act as viral replication hubs [2]. Pressure for 
selection of DRM may be limited at these sites, due to the low drug concentrations. 
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LLV in patients on ART has been associated with elevated levels of activated CD8+ T-cells and with 
chronic immune activation. This immune activation may induce extended release of virus from 
infected cells or vice versa, ongoing virus replication may induce and maintain immune activation [3, 
4]. Knowing whether ongoing replication takes place under ART is also important for HIV cure 
research [5, 6]. 
Hypothesizing that active replication will ultimately present as ongoing genetic evolution of 
individual viruses, phylogenetic analysis is the most frequently used tool to prove or reject virus 
replication [7-17]. Already in 1999, Günthard et al. used phylogenetic analysis to demonstrate HIV-1 
evolution, and thus active replication, in some patients with residual viremia on successful ART [11]. 
This finding was later supported by the results of Frenkel et al. and Zhang et al. [10, 17]. Using the 
same phylogenetic approach other studies, however, failed to demonstrate signs of evolution in 
comparable patient populations [7-9, 12-16]. In a recent publication, Lorenzo-Redondo et al. present 
results obtained after next generation sequencing (NGS) of HIV-1 DNA from blood and lymph node 
cells of 3 patients on ART for 6 months [2]. Time-calibrated phylogenetic analysis showed ongoing 
replication in lymphoid tissue despite undetectable VL in plasma. In a later study in children with a 
very homogeneous virus population at initiation of ART, thereby providing a low background to 
detect genetic evolution, no indications for evolution were seen  in 9 of the 10 infants over a follow-
up period of 7 years [18]. It was therefore hypothesized that the time-calibrated method of Lorenzo-
Redondo et al. had skewed the phylogenetic analysis, as the input time point of the samples was 
considered in generating the phylogenetic tree, giving the appearance of evolution even if it is not 
present. These observations stress the importance of including distance based methods to identify 
genetic evolution. 
In addition to phylogenetic analyses, some studies focused on the quantification of 2-LTR circles as 
markers of active virus replication [19-22]. In 2010, the observation that intensification of an ART 
regimen with the integrase inhibitor raltegravir led to an increase in number of 2-LTR circles fueled 
the hypothesis that seemingly suppressive ART failed to completely block virus replication [19]. In the 
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randomized, double-blind, placebo-controlled study of Hatano et al. in 2013 [21], addition of 
raltegravir to a stable ART regimen resulted in a transient increase in 2-LTR circles in 9 of 16 patients. 
Other studies, however, failed to confirm this effect of treatment intensification [20, 22]. Today, the 
hypothesis that the most important sources of residual viremia are long-lived cells that continuously 
express virus or latently infected cells that produce virus when they become activated while the 
presence of ART prevents further replication of this virus is gaining more and more acceptance [12, 
13]. 
While a multitude of studies have investigated the role of virus replication in patients on ART with 
undetectable VL, studies on the sources of LLV above the detection limit of VL assays are limited and 
the conclusions from these studies even more contradicting [7, 15, 23]. Anderson et al. and Mens et 
al. failed to provide proof of ongoing replication, while Tobin et al. did report evidence of genetic 
evolution of plasma virus in a minority of the studied patients (3 of 11). Two studies suffered from a 
low sample number with respectively 1 and 11 LLV individuals included [7, 23]. The extent of patient 
to patient differences in causes of LLV is unknown and it is also unclear whether virus production on 
its own can result in plasma virus concentrations above the cut-off levels of currently applied routine 
VL assays. 
In the current study, we searched for signs of viral replication and evolution in 18 patients with 
persisting LLV. Important added values of this work are the fact that both the plasma and cellular 
compartments of the blood were investigated and that samples were collected over a long period of 
time at multiple time points during LLV as well as before initiation of the ART regimen under which 
LLV manifested. The results of extensive phylogenetic analysis could not provide consistent proof of 
virus replication. 
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METHODS 
Patient selection 
From January 1997 to December 2012, 1393 HIV-infected patients were followed at Ghent University 
Hospital and 621 were on ART during this period. Persisting LLV was retrospectively detected in a 
subpopulation of 71 patients. We defined PLLV as a VL between 20 and 250 copies (c)/mL for at least 
half of minimum 6 VL measurements from six months after the initiation of ART until study inclusion 
(January 2013) [1]. The VL was determined with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 
test v2 (Roche, Basel, Switzerland; limit of detection: 20 c/mL). Longitudinal sequence analysis during 
LLV was attempted for 28 patients randomly selected from the PLLV patients. Extensive phylogenetic 
and sequence analysis was then performed on the 18 patients for whom at least 3 env and pol 
sequences were obtained. 
All analyses were performed retrospectively on stored plasma and buffy coat samples. The treating 
clinicians of the included patients were free to adapt the ART regimen during LLV. All patients 
received intensive individual counselling, including guidance on adherence, food restrictions and 
interference with other products, in order to exclude potential sources of reduced exposure to ART. 
Study design 
To be able to amplify and sequence two regions of the HIV genome (pol and env) from samples with 
very low viral load, an ultrasensitive Sanger sequencing protocol was developed and used for all 
plasma samples collected during LLV. For the samples collected pre-ART, standard population Sanger 
sequencing was performed. In-depth characterization of the virus population present at initiation of 
ART was done by next generation sequencing (NGS) of the last plasma sample collected before 
starting ART (baseline sample). 
Because of expected low concentrations of viral DNA in blood cells collected on ART and because a 
longer sequence length allows better identification and elimination of sequences from defective 
viruses, limiting dilution sequencing was chosen over NGS for characterization of the HIV DNA 
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genetic variability. This limiting dilution DNA sequencing was only preformed for a selection of 8 
patients with LLV of over at least 5 years and for whom buffy coat samples were available from at 
least 3 time points with an interval of 2 years. 
Sequencing of HIV-1 pol and env gene fragments 
Standard Sanger sequencing of viral RNA 
HIV-1 RNA was extracted from EDTA plasma using the High Pure Viral RNA kit (Roche, Basel, 
Switzerland) according to the manufacturer's instructions. For samples with a VL of <10,000 c/mL, 
500 µL of plasma was ultracentrifuged for 1 hour (23,600 × g at 4 °C), after which the pellet was 
suspended in 200µL of phosphate buffered saline (PBS). For samples with a VL of >10,000 c/mL, RNA 
was extracted from 200 µl of plasma without ultracentrifugation. 
Amplification of pol and env was performed using an in-house nested PCR protocol. Briefly, 10 µL of 
the 50 µL RNA extract was subjected to reverse transcription and amplification using the Titan One 
tube RT-PCR system (Roche, Basel, Switzerland) with a combination of 4 primers. The inner PCR 
reaction was performed using 2 µL of the outer PCR product and 4 nested primers. Sequencing of the 
amplicons was performed with the BigDye® Terminator Cycle Sequencing kit v. 3.1 (Life Technologies, 
Carlsbad, CA, USA) and sequencing products were analyzed on the ABI3130XL Genetic analyzer 
(Applied Biosystems, Foster City, CA, USA). Chromatograms were checked and edited manually using 
SmartGene (IDNS™) software (SmartGene GmbH, Zug, Switzerland). Further details on the 
amplification and sequencing procedures as well as the primer sequences can be obtained from the 
authors on request. 
Ultrasensitive Sanger sequencing 
To increase the sensitivity of the Sanger sequencing procedure, the input plasma volume was 
increased to 1.5 mL and the ultracentrifugation time to 2 hours. The elution volume of the extraction 
was reduced from 50 µL to 25 µL and 2 µL of MS2 RNA (Roche, Basel, Switzerland) was added as 
carrier. A 3-step nested amplification protocol was used instead of the standard 2-step reaction as 
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previously described [1]. A detailed description of the PCR conditions can be obtained from the 
authors on request. Briefly, 20 µL of RNA extract was subjected to 60 minutes of reverse 
transcription followed by 10 cycles of amplification in a multiplex reaction combining env and pol 
amplification. Ten µL of the obtained amplicon was then used as input material for two second round 
40 cycle amplifications, one with env primers and one with pol primers. Finally, 2 µL of the second 
round reactions was used as input material for third round 40 cycle amplifications with nested 
primers. 
Next generation sequencing of viral RNA 
In-depth env sequencing of viral RNA isolated from the baseline samples was done using the Roche 
454 GS Junior next generation sequencing system as described before [24]. Reads were trimmed to 
333 nucleotides spanning the env HXB2 nucleotide positions 7,002 to 7,334. In-house software was 
used to correct errors in homopolymer stretches, using Sanger sequences from each patient as 
references. Identical reads were clustered and counted. All variants with at least 2 reads and 
comprising more than 0.2% of the total number of reads were included in phylogenetic analysis. 
Single genome sequencing of viral DNA 
In-depth env sequencing of PBMC-associated HIV-1 DNA was done using limiting dilution 
amplification. Briefly, DNA was extracted with the QIAamp Blood Mini kit (Qiagen, Hilden, Germany) 
from 200 µL of buffy coat and eluted in 200 µL elution buffer according to the manufacturer's 
instructions. For limiting dilution sequencing, the DNA extract was diluted until no more than 30 to 
40% of the nested PCR reactions were positive [25]. Primers and PCR conditions were the same as for 
the standard Sanger sequencing protocol used to amplify env from plasma RNA, but the reverse 
transcription step was omitted. 
Phylogenetic analysis 
All env and pol sequences, from plasma viral RNA and cellular DNA from the different collection 
points before ART initiation and during the course of LLV, were aligned using MUSCLE software 
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(v3.8.31) [26]. Alignments were manually edited and trimmed to 333 nucleotides for env and 573 
nucleotides for pol using BioEdit software (v7.0.9) [27]. Shorter sequences and sequences with stop 
codons or gaps larger than a nucleotide triplet were removed from the alignments. The best-fitting 
nucleotide substitution model was selected with jModeltest software (v2.1.7) [28, 29], using the 
Akaike Information Criterion (AIC) and phylogenetic trees were inferred using PhyML software (v3.0) 
[30]. The trees were visualized and rooted using reference sequences from HIV-1 group M subtypes 
with Mega 6 software (v6.0) [31]. Bootstrap analysis was performed on 100 replicates using PhyML 
on the E-Biothon platform [32]. 
To assess temporal structure in the trees, root-to-tip (RTT) distances were calculated based on the 
ML phylogeny using TreeStat software (v1.2) and plotted against time [33]. In addition pairwise 
genetic distances were estimated from the sequence alignment with the Tamura-Nei model as 
implemented in MEGA 6. To visualize tree expansion over time, temporal tree graphs were 
constructed using the final maximum likelihood phylogenetic env tree as backbone. Onto this 
backbone, the sequences from different sampling points were added in a time-dependent order 
(Figure 1). 
Coreceptor tropism analysis 
The viral coreceptor tropism was determined using the individual env sequences and the 
geno2pheno [coreceptor] algorithm [34]. As recommended by the European Consensus Group on 
clinical management of HIV-1 tropism testing, a false positive rate cut-off of 10% was used for 
classification as CCR5- or CXCR4-using virus [35]. 
Statistical analysis 
Linear regression analysis as implemented in SPSS v.22 (IBM, NY, USA) was used to determine if the 
slopes of the RTT distances and the pairwise distances in function of time significantly differed from 
zero. 
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Nucleotide sequence accession numbers  
All HIV-1 pol and env sequences derived in this study have been submitted to GenBank and were 
assigned accession numbers # to # (submission pending). 
RESULTS 
Patient characteristics 
Detailed information on the included patients can be found in Table 1. The median time of follow-up 
was 4.8 years (IQR 3.5 - 5.6). The median VL at the time of initiation of the ART regimen that resulted 
in LLV was 5.1 log10 c/mL (IQR 4.9 - 5.4) and the median VL during LLV was 51 c/mL (IQR 37 – 82; only 
for the measurements above the detection limit). The minimum duration of LLV at study inclusion 
(January 2013) was 2.5 years. All patients were infected with subtype B virus, 6 were treatment 
experienced but had interrupted all medication before initiation of the ART regimen resulting in LLV. 
There was no history of drug resistance development. 
Amplification and sequencing 
Pol and env sequencing was done on respectively 93 (median 5 per patient; IQR 3 – 7, median 
collection time 3.1 years) and 67 (median 4 per patient; IQR 2 – 5, median collection time 1.8 years) 
pre-ART plasma samples. Env and pol sequencing was successful for respectively 141 (55.7%) and 126 
(49.8%) of the 253 plasma samples collected during LLV. The time interval between the successfully 
sequenced LLV samples was minimum 14 days and maximum 3.8 years. NGS of viral RNA collected at 
baseline was successful for all 18 patients and resulted in a total of 17,773 reads (median 596 per 
patient; IQR 526 – 896) representing 754 unique variants (median 38 per patient; IQR 31 – 48). For 
the 8 patients with an on-ART follow-up of at least 5 years, the limiting dilution sequencing of viral 
DNA samples resulted in a total of 349 DNA clones (median 45 per patient; IQR 39 – 48). All 
information on the number of sequences included in the phylogenetic analysis is listed in Table 1. 
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Phylogenetic analysis 
Maximum likelihood env and pol phylogenetic trees were constructed with all available RNA and DNA 
sequences after removal of variants with gaps or stop codons. Visual examination of both trees 
revealed profound per patient clustering except for patients 03 and 17 (Supplemental figure S1). 
These two patients were known to be part of a larger MSM transmission cluster, explaining their 
close genetic homology. No indications for inter-patient contamination during the amplification or 
sequencing process could be inferred. Detailed phylogenetic trees of env sequences are provided in 
Supplemental figure S2. 
If ongoing viral replication occurs during LLV, it is expected that viral variants isolated over time 
during LLV would show close genetic linkage. Phylogenetic clustering with bootstrap support higher 
than 70% is an indicator for genetic linkage [36], therefore clusters fulfilling this criterion were 
identified and examined for presence of sequences from samples collected during LLV (Table 2). Of 
the 46 and 7 clusters identified respectively in the env and pol trees, 11 and 6 contained at least 2 
LLV sequences. For 2 patients (06 and 10) all env LLV sequences were present in a single cluster. 
Overall, clusters with 2 or more LLV sequences were detected in 11 patients. They contained LLV 
sequences sampled over a median period of 2.25 years for env (IQR 0.33 – 2.75 years) and 1.71 years 
for pol (IQR 0.61 – 3.82 years). Clusters were either composed uniquely of LLV sequences (patients 
07, 15 and 23 for env and patients 01, 05, 14, 18 and 20 for pol) or contained a mixture of pre-ART, 
LLV RNA and LLV DNA sequences (patients 01, 05, 06, 10 and 11 for env and patient 06 for pol). 
Detecting time-dependent evolution 
Close genetic linkage of the LLV viruses does not directly imply evolution. To evidence evolution, 
additional proof of genetic changes building up in a temporal manner must be demonstrated. Visual 
inspection of env temporal tree graphs clearly revealed absence of evolution in patient 10. For this 
patient, all obtained env LLV sequences were identical and an identical variant was also present in 
the baseline plasma sample. In 12 patients (01, 02, 03, 05, 07, 14, 15, 17, 18, 20, 21 and 23), 
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consecutive addition of LLV sequences resulted in an at random dispersal of these sequences over 
the tree, intermingled between pre-ART and baseline variants. In 5 patients (06, 09, 11, 19 and 22), 
the env LLV sequences showed evidence of clustering but there was no association between the 
position of the LLV sequences in the cluster and the sampling time. Figure 1 shows the expansion of 
the phylogenetic tree of env sequences through time for 2 representative patients. 
Linear regression analysis of the RTT distances of LLV env RNA sequences in function of time revealed 
significantly increasing RTT distances in patients 07 (p = 0.001) and 15 (p = 0.011) but failed to 
indicate such a correlation in the other 16 patients. The same analysis performed on the LLV pol 
sequences showed a significant association between the RTT distances and time in 3 patients (10 (p = 
0.032), 18 (p = 0.028) and 22 (p = 0.010)) (Table 3). For the env DNA sequences RTT distance analysis 
failed to detect any sign of evolution but linear regression analysis of the pairwise distances showed 
a significant positive slope in 3 patients (05, 14 and 18 (p < 0.001)) and a significant negative slope, 
suggesting loss of diversity, in 4 patients (03 (p < 0.001), 15 (p < 0.001), 17 (p = 0.002) and 20 (p = 
0.034)). For one patient (21) the slope was not significantly different from zero. 
Searching for sequence homology 
Repetitive identification of identical pol and/or env sequences at different time points during LLV was 
observed in 11 patients. The time span separating the collection of the first and last of these identical 
sequences ranged from 0.2 to 7.5 years (median 1.0 years, IQR: 0.8 – 3.8 years) when considering the 
results of pol sequencing and from 0.1 to 2.8 years (median 1.3 years, IQR: 0.3 – 2.4 years) for the 
env sequences. In 8 patients (01, 05, 11, 14, 15, 20, 21 and 22), detection of these repetitive variants 
alternated with detection of other variants. Only in patient 10, the env sequence remained identical 
over all 9 LLV samples. In the DNA samples collected during LLV, predominant clones were observed 
at different sampling points in 4 patients: 03 (43 of the 50 sequences), 05 (5 of 44 sequences), 15 (11 
of 48 sequences) and 20 (5 of 45 sequences). The clonal DNA sequences however were not identical 
to the clonal RNA sequences observed in the same patient. 
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Apart from investigating indications of viral evolution we also tried to identify the potential source of 
virus isolated during LLV. This was done by examining genetic homology between LLV RNA 
sequences, baseline RNA sequences and LLV DNA sequences. For only 4 of the 18 patients (10, 11, 14 
and 23) the env sequence of at least one time point during LLV was identical to one of the variants 
detected in plasma at baseline. For patient 14, the predominant pol LLV variant was also detected in 
pre-ART samples. For 7 of the 8 patients with DNA sequences available one of the env variants 
detected in DNA was identical to the sequence of at least one time point during LLV. 
Coreceptor use during LLV 
Consistent CCR5-use over the whole LLV period was observed in 12 of the 18 patients, consistent 
CXCR4-use in 1 patient (Table 4). In the remaining 5 patients, CCR5-using and CXCR4-using variants 
alternated during LLV. In one patient with alternating CCR5 and CXCR4-use during LLV, only CCR5-
using variants were detected in the pre-ART and baseline population. Of the 6 patients with a mixed 
population of CCR5 and CXCR4-using viruses pre-ART and at baseline, alternating detection of CCR5 
and CXCR4 variants during LLV was observed in 4. 
An overview of the results of all markers of genetic evolution that were analyzed is presented in 
Table 5. 
DISCUSSION 
Patients on ART may present with small amounts of virus in their plasma over a longer period of time 
without evolution to therapy failure. The source of this virus remains uncertain. In this report we 
present 18 patients with long-term persisting LLV on ART for whom the virus population was 
characterized extensively using population sequencing and NGS of viral RNA, and limiting dilution 
sequencing of viral DNA. The viral RNA and DNA samples were extracted from longitudinally 
collected blood samples over a very long time span pre- and on-ART. The genetic linkage between 
the viral sequences was defined by phylogenetic analysis in the assumption that ongoing replication 
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would result in clustering of the sequences collected during LLV with a time-ordered evolutionary 
trend away from the most recent common ancestor. Additionally, increasing diversity of the proviral 
DNA was expected in case of evolution. 
Although the majority of studies attempting to investigate viral replication in patients on ART rely on 
phylogenetic analysis [7-14, 16, 23], there is no standard approach on how to reliably evidence 
genetic evolution. Conclusions are often based on visual inspection of the phylogenetic trees for 
presence or absence of intermingling of sequences collected at different time points [7-9, 13, 16]. 
Alternatively, the most commonly used mathematical methods calculate the divergence (pairwise 
distances) from the sampled sequences to the inferred most recent common ancestor [10, 11, 23], 
the RTT distances from the inferred tree [12, 13], or the overall evolution of pairwise distances 
between sequences of different sampling points [9, 13, 16, 17]. The identification of genetic 
evolution following slow rates of virus replication in a background of large overall genetic variability 
is however challenging. We therefore used a combined approach applying different tools to assess 
genetic evolution and analyzed two regions of the HIV genome, the more conserved pol gene and the 
highly variable env gene. 
For 8 of the 18 patients none of the assessed markers revealed evidence of temporal genetic 
evolution over a median period of 4.8 years of LLV. For 8 patients, the result of one marker pointed 
towards virus evolution but this was never confirmed for both the env and pol sequences and was 
not supported by the outcome of the other measurements. For 2 patients the results of 2 markers 
indicated genetic evolution. In case of patient 18, RTT analysis of pol and pairwise distance analysis of 
the DNA sequences suggested increasing diversity but the phylogenetic tree revealed profound 
intermingling of the sequences with the pre-ART sequences. In patient 05, bootstrap analysis 
revealed clustering of on-ART RNA sequences and pairwise distance analysis of the DNA sequences 
indicated increasing variability, but no significant temporal structure could be detected by RTT 
analysis of the RNA sequences. 
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Coreceptor use analysis of virus isolated during LLV has, to our knowledge, not been done before. 
We used the obtained env sequences to predict the coreceptor preference of the viral isolates. In 6 
patients (02, 03, 06, 07, 10, 15) NGS revealed the presence of a mixture of CCR5- and CXCR4-using 
variants before ART initiation. It was surprising to see that in 3 of these 6 patients (02, 03 and 06) 
CCR5 and CXCR4-using variants were detected alternately over time during LLV. This finding pleads 
against viral evolution because in case of evolution and concomitant selective pressure, one would 
expect the consistent detection of descendants of the same strain with unchanged coreceptor use or 
possibly a single switch at a certain time point. 
So overall we were unable to provide firm arguments for the existence of virus replication and 
resulting genetic evolution during longer episodes of persistent low viremia under ART. If not virus 
replication but virus production is considered to be the major contributor to LLV, potential sources of 
the plasma virus may be long-lived HIV-infected cells continuously releasing virus or latently infected 
cells that become activated and produce virus before dying [37]. In both cases one would expect 
considerable intermingling of the sequences from viruses isolated at different time points as well as 
intermingling of viral RNA and DNA sequences. This intermingling was indeed observed in all 8 
patients with both RNA and DNA tested. A hypothesis formulated recently is that the process of 
stochastic virus production may be driven to a large extent by clonally expanded cells [8, 12, 13, 23]. 
Already in 2006, Bailey et al. described the persistence of a predominant plasma clone in patients on 
ART with a viral load <50 c/mL [8]. More recently, integration site analysis provided further 
compelling evidence for the presence of clonally expanded HIV-infected cells in vivo [38-40]. In 11 of 
the 18 patients we observed identical RNA sequences at different time points during LLV, often 
spread over a long time span, supporting the idea of production from clonally expanded cells. 
However, the origin of these predominant plasma sequences could be traced to the cellular 
compartment only in 2 patients, indicating that the producing cells do not constitute the majority of 
infected cells in the blood. 
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Whether clonally expanded cells are capable of producing replication competent virus remains a 
subject of debate [41, 42]. There are indications that a large majority of proviruses in these expanded 
cell clones is defective [12, 38, 39, 42]. But Simonetti et al. recently showed a highly expanded CD4+ 
T cell clone carrying replication competent provirus in 1 patient and Kearney et al. found that in 2 
patients who underwent treatment interruption the origin of rebound plasma virus was an expanded 
cell clone [43, 44]. Whether patients with higher numbers of clonally expanded cells are more prone 
to LLV under ART is a hypothesis that needs to be investigated further. 
A drawback of our study is that only bulk sequencing was performed on the plasma samples 
collected during LLV. As a result, it is likely that only the most represented variant is sequenced and 
this may have reduced the sensitivity to detect evolution over time. Ambiguous nucleotide positions 
were detected at 1 or more positions in 59 of the 143 env sequences, an indication that in these 
cases a mixture of variants was present. Another shortcoming is that the env phylogenetic analysis 
was performed on short sequences because of the limited read length of the NGS. Recently, Laskey 
et al. showed that sequence identity in subgenomic regions of the viral genome does not guarantee 
clonality across the full viral genome [45]. So although we sequenced a highly variable part of the env 
gene we cannot exclude missing some diversity. 
The median sequencing depth of our NGS analysis was 596 reads per patient. This was considered 
sufficient for a global estimate of the viral variability and to characterize the most represented viral 
strains at initiation of ART, which was the goal of the analysis. Low-frequent viral variants will be 
missed, but this will not impact the conclusions regarding viral evolution during LLV as this conclusion 
is based on the phylogenetic relationship between the LLV sequences. 
CONCLUSIONS 
Taken together, the results of this study failed to support presence of active virus replication and 
evolution in patients with LLV above the detection limits of commercial assays while being on ART. 
This finding is in line with our previous observations that in the majority of cases of LLV on ART we 
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could not document treatment failure or drug resistance [1]. Today, about 3 years after closure of 
sample inclusion, 10 of the 18 study patients still present recurrent LLV. Eight patients have evolved 
to a continuously undetectable viral load (<20 c/mL), 6 of them without ART changes and 2 after a 
treatment adaptation. None of the 18 patients has developed virologic failure or drug resistance. 
All these observations support the hypothesis that residual viremia mainly results from a process of 
virus production. It is however important to emphasize that, although generally used for these 
purposes, the power of phylogenetic analysis to exclude very low levels of virus replication may be 
limited. Absence of evidence is therefore not necessarily evidence of absence and future research 
should concentrate on the development of alternative methods for the detection or exclusion of 
active replication in the presence of ART. 
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FIGURES 
Figure 1. Temporal tree graphs. Expansion of the phylogenetic tree of env sequences through time 
shown for 2 representative patients: patient 23 (a) and patient 06 (b). ART initiation is depicted as 
time 0. The backbone of the phylogenetic tree with all pre-ART sequences, regardless of their 
sampling time, is copied and viral variants of each time point during LLV are consecutively added. 
Pre-ART sequences are shown as filled grey circles, baseline NGS variants as diamonds and LLV 
Sanger sequences as filled black circles. 
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Table 1: Overview of patient characteristics 
Patient 
Follow-
up 
(years) 
Pre-ART 
VL (c/mL) 
LLV VL (c/mL)a 
Treatment 
experienced 
at baseline 
LLV 
burden 
(%)b 
Number of sequences included in phylogenetic analysis 
env pol 
pre-ART ART-startc LLV Interval (days)d DNA pre-ART LLV Interval (days)d 
03 5.7 149,000 47.0 [26 – 200] - 59 8 20 (219) 8 210 [158 - 304] 50 7 8 96 [84 – 203] 
21 9.2 >100,000 43.0 [20 – 131] yes 74 4 41 (317) 5 571 [363 – 805] 49 6 9 347 [245 – 410] 
15 9.8 291,000 47.0 [26 – 211] - 80 5 32 (530) 9 264 [137 – 447] 48 3 6 387 [266 – 1106] 
17 5.3 219,000 34.0 [20 – 68] yes 52 5 39 (525) 5 218 [115 – 318] 39 7 4 326 [234 – 541] 
18 5.6 105,000 38.0 [34 – 93] - 72 5 31 (455) 9 220 [157 – 304] 36 5 6 238 [53 – 461] 
05 6.2 >100,000 43.0 [24 – 203] - 52 1 16 (545) 5 261 [120 – 532] 44 4 6 171 [122 – 511] 
20 5.5 35,800 59.0 [29 – 106] - 68 6 36 (612) 8 231 [63 – 332] 45 8 5 63 [28 – 101] 
14 5.7 104,000 80.5 [24 – 218] yes 90 7 65 (970) 12 202 [121 – 233] 38 10 8 227 [185 – 271] 
01 3.3 1,086,005 65.0 [21 – 114] yes 89 3 17 (219) 6 106 [84 – 286] NA 5 10 63 [14 – 91] 
02 4.7 291,000 72.0 [24 – 220] yes 88 5 42 (579) 11 118 [101 – 170] NA 10 13 97 [72 – 114] 
06 4.7 210,000 51.5 [29 – 158] - 81 1 49 (1573) 9 123 [90 – 152] NA 5 12 76 [53 – 136] 
07 4.8 70,000 48.0 [21 – 250] - 67 1 71 (1087) 8 91 [88 – 213] NA 5 4 182 [109 – 221] 
09 4.4 29,700 62.0 [23 – 210] - 41 4 34 (840) 7 187 [105 – 341] NA 4 6 127 [98 – 372] 
10 3.3 67,799 68.0 [28 – 293] - 53 2 88 (6284) 9 90 [57 – 125] NA 3 7 71 [47 – 152] 
11 4.1 152,170 41.0 [22 – 75] - 44 0 45 (700) 7 121 [104 – 263] NA 1 3 397 [295 – 500] 
19 3.3 54,110 32.0 [23 – 71] yes 91 6 35 (899) 10 125 [104 – 167] NA 6 9 140 [119 – 176] 
22 2.2 374,584 56.5 [22 – 190] - 90 2 64 (886) 4 309 [206 – 349] NA 3 6 104 [52 – 172] 
23 3.2 1,905,647 45.5 [23 – 82] - 70 2 29 (533) 9 110 [85 – 177] NA 1 4 467 [289 – 512] 
VL, viral load; c/mL, copies/mL; LLV, low-level viremia; ART, antiretroviral therapy 
a Median [min – max] 
b Percentage of VL measurements >20 c/mL compared to the total number of VL measurements performed during follow-up 
c NGS clones (# corresponding reads). 
d Median [IQR] time interval between sequenced LLV samples. 
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Table 2: Results of the phylogenetic cluster analysis 
Patient 
ENV PRRT 
Total # 
clusters 
# clusters 
containing 
≥ 2 LLV 
# clustered LLV 
sequencesa 
Bootstrap 
value 
Time span 
(years) 
Total # 
clusters 
# clusters 
containing 
≥ 2 LLV 
# clustering LLV 
sequencesa 
Bootstrap 
value 
Time span 
(years) 
03 2 - - - - - - - - - 
21 3 - - - - - - - - - 
15 2 1 6/9 100 2.25 - - - - - 
17 1 - - - - - - - - - 
18 5 - - - - 1 1 2/6 70 2 
05 2 1 4/5 87 4.25 1 1 4/6 75 4.25 
20 5 1 2/8 91 1.25 1 1 4/5 76 0.67 
14 - - - - - 1 1 5/8 74 3.67 
01 2 1 4/6 75 2.5 1 1 3/10 95 0.42 
02 5 - - - - - - - - - 
06 2 1 9/9 75 3.83 1 1 2/12 78 1.42 
07 5 3 2/8 87 0.08 - - - - - 
   2/8 77 0.17      
   2/8 100 0.33      
09 4 - - - - - - - - - 
10 2 1 9/9 100 2.5 1 - - - - 
11 2 1 6/7 96 2.75 - - - - - 
19 3 - - - - - - - - - 
22 - - - - - - - - - - 
23 1 1 2/9 75 2.08 - - - - - 
a Depicted as number of LLV sequences in the cluster/total number of analyzed LLV sequences 
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Table 3: Results of linear regression analysis of root-to-tip and mean pairwise distance 
Patient 
RTT distance (Lin. Reg.) 
RTT distance DNA (Lin. Reg.)a PW distance DNA (Lin. Reg.)a 
enva pola 
03 -0.010 (0.350) 5.63E-11 (0.354) -5.039E-11 (0.221) -0.004 (<0.001) 
21 0.002 (0.497) 1.05E-11 (0.311) -2.687E-11 (0.616) 0.000 (0.730) 
15 0.003 (0.011) -1.09E-11 (0.055) 1.258E-10 (0.283) -0.002 (<0.001) 
17 -0.004 (0.648) 7.41E-11 (0.062) 7.882E-11 (0.399) -0.002 (0.002) 
18 0.001 (0.534) 1.87E-10 (0.028) -6.498E-11 (0.140) 0.003 (<0.001) 
05 -0.002 (0.387) 1.78E-11 (0.695) 2.321E-10 (0.123) 0.003 (<0.001) 
20 0.006 (0.324) -3.11E-12 (0.981) -2.369E-11 (0.831) -0.001 (0.034) 
14 -0.004 (0.455) 5.32E-11 (0.700) -4.793E-12 (0.932) 0.004 (<0.001) 
01 0.044 (0.366) -1.37E-10 (0.124) NA NA 
02 -0.012 (0.565) 6.65E-11 (0.264) NA NA 
06 -0.002 (0.958) -3.63E-10 (0.313) NA NA 
07 0.076 (0.001) 1.05E-13 (0.853) NA NA 
09 0.030 (0.309) 1.59E-10 (0.117) NA NA 
10 NA 5.08E-10 (0.032) NA NA 
11 0.037 (0.066) 1.16E-10 (0.149) NA NA 
19 -0.010 (0.029) 6.72E-11 (0.118) NA NA 
22 -0.019 (0.403) 5.44E-11 (0.010) NA NA 
23 -0.009 (0.796) 6.95E-11 (0.122) NA NA 
Lin. Reg., Linear regression analysis; RTT, root-to-tip; LLV, low-level viremia; PRRT, protease and reverse transcriptase; ART, antiretroviral 
therapy; PW distance, pairwise distance; NA, not applicable 
a Slope (p-value) 
Significant values shown in bold 
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Table 4: Results of coreceptor tropism analysis pre-ART (RNA, DNA) and during LLV (RNA) 
Patient Pre-ART tropism LLV 1 LLV 2 LLV 3 LLV 4 LLV 5 LLV 6 LLV 7 LLV 8 LLV 9 LLV 10 LLV 11 LLV 12 
03 R/X R X X X X R X R - - - - 
21 R R R R R R - - - - - - - 
15 R/X X X R R R R R R R - - - 
17 R R R R R R - - - - - - - 
18 R R R R R R R R R R - - - 
05 R R R R R R - - - - - - - 
20 R R R R R R R R R - - - - 
14 R R R R R R R R R R R R R 
01 R R R X R R R - - - - - - 
02 R/X X X R X X X X X R X X - 
06 R/X R R R R R R X R X - - - 
07 R/X X X X X X X X X - - - - 
09 R R R R R R R R - - - - - 
10 R/X R R R R R R R R R - - - 
11 R R R R R R R R - - - - - 
19 R R R R R R R R R R R - - 
22 R R R R R  - - - - - - - 
23 R R R R R R R R R R - - - 
X, CXCR4-tropic virus; R, CCR5-tropic virus 
LLV1 to 12: consecutive sampling, time interval differs between patients 
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Table 5: Interpretation of the results of the performed analyses: virus evolution indicated or not 
Patient 
Tree 
topology 
RTT 
distances 
DNA 
Pairwise 
distances 
Viral tropism 
03    Alternating  
21    Constanta 
15  ✓  Alternating  
17    Constanta 
18  ✓ ✓ Constanta 
05 ✓  ✓ Constanta 
20    Constanta 
14   ✓ Constanta 
01 ✓  NA Alternating  
02   NA Alternating  
06 ✓  NA Alternating  
07  ✓ NA Constanta 
09   NA Constanta 
10  ✓ NA Constanta 
11 ✓  NA Constanta 
19   NA Constanta 
22  ✓ NA Constanta 
23   NA Constanta 
, absence of indications for virus evolution; ✓, presence of indications for virus 
evolution; NA, not applicable 
a No indication against or in favor of virus evolution. 
 
